Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions-Reference-Cited by-同舟云学术

Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions

Published:2023-02 Issue:1 Volume:8 Page:100764
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Castelo-Branco L.,Morgan G.,Prelaj A.,Scheffler M.,Canhão H.,Van Meerbeeck J.P.,Awada A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference94 articles.

1. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs;Haslam;JAMA Netw Open,2019

2. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer;Wang;BMC Cancer,2021

3. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

4. Immuno-oncology clinical trial design: limitations, challenges, and opportunities;Baik;Clin Cancer Res,2017

5. Lung cancer statistics;Torre,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biosynthesis of copper oxide nanoparticles using Tecoma stans flower extract and its antibacterial, anticancer, and photocatalytic activities;Biocatalysis and Agricultural Biotechnology;2024-06

2. Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort;ESMO Open;2024-05

3. Immune Checkpoint Inhibitors: A Narrative Review on PD-1/PD-L1 Blockade Mechanism, Efficacy, and Safety Profile in Treating Malignancy;Cureus;2024-04-12